Sarepta Therapeutics Inc. (SRPT)
Sarepta Therapeutics' stock falls after patient dies of liver failure
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
On Tuesday, Sarepta Therapeutics, Inc. SRPT stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
Sarepta says patient dies after treatment with gene therapy
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
Sarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock Weakness
Sarepta Therapeutics' stock is at 52-week lows despite strong Q4 earnings and promising clinical updates, reflecting broader biotech sector challenges and investor sentiment. Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD, and DM1, with significant market potential, though not as large as DMD.
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Gena Wang - Barclays Andrew Tsai - Jefferies Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Joe Schwartz - Leerink Partners Gil Blum - Needham & Company Ritu Baral - TD Cowen Brian Skorney - Baird David Hoang - Deutsche Bank Ry Forseth - Guggenheim Securities Priyanka Grover - JPMorgan Biren Amin - Piper Sandler Gavin Clark-Gartner - Evercore Sami Corwin - William Blair Leo Watson - Mizuho Operator Good afternoon. And welcome to the Sarepta Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago.
Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by the gene therapy. Despite past valuation concerns, Sarepta's current market cap of $11.4bn is justified, with potential for a >50% gain by YE25. Elevidys' high price and mixed clinical results raise concerns, but totality of evidence suggests it may be the best available treatment for DMD, with no immediate rivals.
Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan
Sarepta + Arrowhead +0.18 (+0.97%)
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
